billS4993Event Wednesday, July 15, 2026Analyzed

A bill to direct the Secretary of Veterans Affairs to establish a precision oncology program for cancer of the prostate at the Department of Veterans Affairs, and for other purposes.

Neutral

Summary

S. 4993, the POPCaP Act, is an early-stage bill authorizing a VA precision oncology program for prostate cancer. It has been referred to committee with no funding specified, and no publicly traded companies are directly impacted at this stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S. 4993 is an early-stage authorization bill with no funding specified.
  • 2.No publicly traded companies are directly impacted by the bill's current text.
  • 3.The bill's progress depends on committee action and subsequent appropriations.

Market Implications

The bill has no immediate market implications. If it advances, companies providing precision oncology diagnostics or therapies (e.g., $EXAS, $GH, $NSTG) could see indirect benefits from VA contracts, but this is highly speculative and not actionable now.

Full Analysis

On July 15, 2026, Senator Jerry Moran (R-KS) introduced S. 4993, the Precision Oncology Program for Cancer of the Prostate Authorization Act of 2026. The bill was read twice and referred to the Committee on Veterans' Affairs. It directs the Secretary of Veterans Affairs to establish a precision oncology program for prostate cancer within the VA, designating 17 VA medical centers as provisional centers of excellence. The bill is in an early legislative stage with no committee action or markup yet. It authorizes the program but does not specify any funding amount, meaning actual appropriations would require a separate bill. The primary impact is on VA healthcare operations, not private sector companies. No publicly traded companies are directly named or obligated by the bill's text. The VA may contract with diagnostic or pharmaceutical companies for precision oncology services, but this is speculative at this stage. The bill has one cosponsor, Senator Angus King (I-ME), and no companion bill in the House. Legislative momentum is low given the early stage and lack of funding authorization.

Key Legislators

Sen. Moran, Jerry [R-KS]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →